Endostatin specifically targets both tumor blood vessels and lymphatic vessels

被引：20
作者：
Zhuo W. [1 ,2 ,3 ]
Chen Y. [1 ,2 ,3 ]
Song X. [1 ,2 ,3 ]
Luo Y. [1 ,2 ,3 ]
机构：
[1] National Engineering Laboratory for Anti-tumor Protein Therapeutics
[2] Beijing Key Laboratory for Protein Therapeutics
[3] Cancer Biology Laboratory, School of Life Sciences, Tsinghua University
来源：
Frontiers of Medicine | 2011年 / 5卷 / 4期
基金：
国家高技术研究发展计划(863计划); 中国国家自然科学基金;
关键词：
angiogenesis; endostatin; internalization; lymphangiogenesis; nystatin; tumor;
D O I：
10.1007/s11684-011-0163-5
中图分类号：
学科分类号：
摘要：
Endostatin, a 20 kDa C-terminal fragment of collagen XVIII, was first identified as a potent angiogenic inhibitor. The anti-angiogenic function of endostatin has been well documented during the past decade. Recently, several studies demonstrated that endostatin also inhibits tumor lymphangiogenesis and lymphatic metastasis. However, the exact mechanism that endostatin executes its anti-angiogenic and anti-lymphangiogenic functions remains elusive. In the current mini-review, we briefly summarize recent novel findings, including the functions of endostatin targeting not only angiogenesis but also lymphangiogenesis, and the underlying mechanism by which endostatin internalization regulates its biological functions. © 2011 Higher Education Press and Springer-Verlag Berlin Heidelberg.
引用
收藏
页码：336 / 340
页数：4
相关论文
共 47 条
  • [1] O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., Folkman J., Endostatin: an endogenous inhibitor of angiogenesis and tumor growth, Cell, 88, 2, pp. 277-285, (1997)
  • [2] Folkman J., Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action, Exp Cell Res, 312, 5, pp. 594-607, (2006)
  • [3] Fu Y., Chen Y., Luo X., Liang Y., Shi H., Gao L., Zhan S., Zhou D., Luo Y., The heparin binding motif of endostatin mediates its interaction with receptor nucleolin, Biochemistry, 48, 49, pp. 11655-11663, (2009)
  • [4] Fu Y., Luo Y., The N-terminal integrity is critical for the stability and biological functions of endostatin, Biochemistry, 49, 30, pp. 6420-6429, (2010)
  • [5] Fu Y., Tang H., Huang Y., Song N., Luo Y., Unraveling the mysteries of endostatin, IUBMB Life, 61, 6, pp. 613-626, (2009)
  • [6] Fukumoto S., Morifuji M., Katakura Y., Ohishi M., Nakamura S., Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells, Clin Exp Metastasis, 22, 1, pp. 31-38, (2005)
  • [7] Brideau G., Makinen M.J., Elamaa H., Tu H., Nilsson G., Alitalo K., Pihlajaniemi T., Heljasvaara R., Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice, Cancer Res, 67, 24, pp. 11528-11535, (2007)
  • [8] Zhuo W., Luo C., Wang X., Song X., Fu Y., Luo Y., Endostatin inhibits tumour lymphangiogenesis and lymphatic metastasis via cell surface nucleolin on lymphangiogenic endothelial cells, J Pathol, 222, 3, pp. 249-260, (2010)
  • [9] Ou J., Li J., Pan F., Xie G., Zhou Q., Huang H., Liang H., Endostatin suppresses colorectal tumor-induced lymphangiogenesis by inhibiting expression of fibronectin extra domain A and integrin α9, J Cell Biochem, 112, 8, pp. 2106-2114, (2011)
  • [10] Achen M.G., McColl B.K., Stacker S.A., Focus on lymphangiogenesis in tumor metastasis, Cancer Cell, 7, 2, pp. 121-127, (2005)
12345